Literature DB >> 17210244

Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies.

Yasmin Akbarali1, Jennifer Matousek-Ronck, Laura Hunt, Leslie Staudt, Morris Reichlin, Joel M Guthridge, Judith A James.   

Abstract

Autoantibodies to centromeric proteins are commonly found in sera of limited scleroderma and other rheumatic disease patients. To better understand the inciting events and possible pathogenic mechanisms of these autoimmune responses, this study identified the common antigenic targets of CENP-A in scleroderma patient sera. Utilizing samples from 263 anti-centromere immunofluorescence positive patients, 93.5% were found to have anti-CENP-A reactivity and 95.4% had anti-CENP-B reactivity by ELISA. Very few patient samples exclusively targeted CENP-A (2.7%) or CENP-B (4.2%). Select patient sera were tested for reactivity with solid phase overlapping decapeptides of CENP-A. Four distinct epitopes of CENP-A were identified. Epitopes 2 and 3 were confirmed by additional testing of 263 patient sera by ELISA for reactivity with these sequences constructed as multiple antigenic peptides. Inhibition CENP-A Western blots also confirmed the specificity of these humoral peptide immune responses in a subset of patient sera. The first three arginine residues (aa 4-6) of CENP-A appear essential for antibody recognition, as replacing these arginines with glycine residues reduced antibody binding to the expressed CENP-A protein by an average of 93.2% (range 80-100%). In selected patients with serial samples spanning nearly a decade, humoral epitope binding patterns were quite stable and showed no epitope spreading over time. This epitope mapping study identifies key antigenic targets of the anti-centromere response and establishes that the majority of the responses depend on key amino-terminal residues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210244      PMCID: PMC1906738          DOI: 10.1016/j.jaut.2006.10.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  33 in total

1.  Fine-specificity of the anti-CENP-A B-cell autoimmune response.

Authors:  M Mahler; R Mierau; M Blüthner
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

2.  Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies.

Authors:  John D Reveille; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2003-06-15

3.  Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.

Authors:  K Russo; S Hoch; C Dima; J Varga; M Teodorescu
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

4.  Immunoglobulin class and pattern of nuclear fluorescence in systemic lupus erythematosus.

Authors:  E N Gonzalez; N F Rothfield
Journal:  N Engl J Med       Date:  1966-06-16       Impact factor: 91.245

5.  Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3.

Authors:  Y Muro; N Azuma; H Onouchi; M Kunimatsu; Y Tomita; M Sasaki; K Sugimoto
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

6.  Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors:  L A Aarden; E R de Groot; T E Feltkamp
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

7.  Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors:  Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

Review 8.  Antibodies in scleroderma: direct pathogenicity and phenotypic associations.

Authors:  Lorinda Chung; Paul J Utz
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

9.  Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants.

Authors:  G A McCarty; J R Rice; M L Bembe; F A Barada
Journal:  Arthritis Rheum       Date:  1983-01

10.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

Authors:  Maureen D Mayes; James V Lacey; Jennifer Beebe-Dimmer; Brenda W Gillespie; Brenda Cooper; Timothy J Laing; David Schottenfeld
Journal:  Arthritis Rheum       Date:  2003-08
View more
  6 in total

Review 1.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

2.  Whither autoimmunity: the lessons of anti-CCP and B cell depletion.

Authors:  Yehuda Shoenfeld; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 3.  Cell damage and autoimmunity: a critical appraisal.

Authors:  Ian R Mackay; Natasha V Leskovsek; Noel R Rose
Journal:  J Autoimmun       Date:  2008 Feb-Mar       Impact factor: 7.094

4.  Clinical and serological evaluation of a novel CENP-A peptide based ELISA.

Authors:  Michael Mahler; Liesbeth Maes; Daniel Blockmans; Rene Westhovens; Xavier Bossuyt; Gabriela Riemekasten; Sandra Schneider; Falk Hiepe; Andreas Swart; Irmgard Gürtler; Karl Egerer; Margrit Fooke; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2010-05-20       Impact factor: 5.156

5.  Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.

Authors:  Federico Perosa; Elvira Favoino; Giovanna Cuomo; Liboria Digiglio; Franco Dammacco; Marcella Prete; Gabriele Valentini; Vito Racanelli
Journal:  Arthritis Res Ther       Date:  2013-07-09       Impact factor: 5.156

6.  Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.

Authors:  Elvira Favoino; Liboria Digiglio; Giovanna Cuomo; Isabella E Favia; Vito Racanelli; Gabriele Valentini; Federico Perosa
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.